RePORT International What’s New

The TB digital platform offers dashboards displaying global TB data—from overall trends to specific sources like prevalence surveys. It brings together data from all countries and makes it easier to access and understand through clear, user-friendly visuals.

A free educational tool for healthcare providers treating pediatric TB. Updated in May 2025, it includes a five-part video series (64 minutes) by Dr. Ann M. Loeffler and downloadable clinical tools and handouts.

Watch webinars, event recordings, and advocacy videos from the Stop TB Partnership.

This session called for increased domestic TB funding in Africa, private sector engagement, and innovation in service delivery, governance, and regulation—underscoring community-driven and politically aligned strategies.

A session from the 78th World Health Assembly focused on new financing models and emerging technologies in TB. Speakers emphasized sustainable investment and digital health tools to improve prevention, diagnosis, and treatment.

The Union has three official journals: >> The International Journal of Tuberculosis and Lung Disease, IJTLD - the leading peer-reviewed journal dedicated to lung health worldwide. >> IJTLD Open - The Union's new Open Access journal for the latest research on TB and lung diseases including asthma, COVID-19 and COPD. >> Public Health Action - the latest operational research on health systems.

TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:

The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB. The Activist Guide reviews the evidence-base behind these regimens, important considerations for key populations affected by TB, the access landscape, and more. The publication is intended to equip advocates with information they need to formulate arguments and push for universal implementation of the best available treatments.

The database provides the most up-to-date information on clinical trials, operational research, and other studies related to TB and MDR-TB.